Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma

OBJECTIVE: Complement C4d-containing fragments have been proposed as diagnostic markers for lung cancer. The purpose of this study was to evaluate the presence of C4d in oropharyngeal (OPSCC) and oral (OSCC) squamous cell carcinomas. SUBJECTS AND METHODS: C4d staining was analyzed by immunohistochemistry in 244 OPSCC surgical specimens. C4d levels were quantified by ELISA in resting saliva samples from 48 patients with oral leukoplakia and 62 with OSCC. Plasma samples from 21 patients with leukoplakia and 30 with oral carcinoma were also studied. RESULTS: C4d staining in OPSCC specimens was associated with nodal invasion (P = 0.001), histopathologic grade (P = 0.014), disease stage (P = 0.040), and focal-adhesion kinase expression (P < 0.001). No association was found between C4d and prognosis. Saliva C4d levels were higher in patients with oral cancer than in subjects with leukoplakia (0.07 +/- 0.07 vs 0.04 +/- 0.03 mu g ml(-1), P = 0.003). The area under the ROC curve was 0.63 (95%CI: 0.55-0.71). Salivary C4d levels in stage IV patients were higher than in patients with earlier stages (P = 0.028) and correlated with tumor size (P = 0.045). Plasma C4d levels also correlated with salivary C4d levels (P = 0.041), but differences between patients with oral cancer and subjects with leukoplakia were not significant (1.26 +/- 0.59 vs 1.09 +/- 0.39 mu g ml(-1), P = 0.232). CONCLUSION: C4d-containing fragments are detected in oral primary tumors and are increased in saliva from patients with OSCC.We thank Amaya Lavin for technical assistance. This work was supported by Foundation for Applied Medical Research (FIMA), Red Tematica de Investigacion Cooperativa en Cancer (RD12/0036/0015, RD12/0036/0025, and RD12/0036/0040), and Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (FEDER, PI11/00618, PI13/00806, PI11/00929, and PI14/01686).Ajona, D.; Pajares, MJ.; Chiara, MD.; Rodrigo, JP.; Jantus Lewintre, E.; Camps, C.; Suarez, C.... (2015). Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. Oral Diseases. 21(7):899-904. doi:10.1111/odi.12363899904217Ajona, D., Pajares, M. J., Corrales, L., Perez-Gracia, J. L., Agorreta, J., Lozano, M. D., … Pio, R. (2013). Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. JNCI: Journal of the National Cancer Institute, 105(18), 1385-1393. doi:10.1093/jnci/djt205Ajona, D., Razquin, C., Pastor, M. D., Pajares, M. J., Garcia, J., Cardenal, F., … Pio, R. (2015). Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLOS ONE, 10(3), e0119878. doi:10.1371/journal.pone.0119878Arantes, L. M. R. B., de Carvalho, A. C., Melendez, M. E., Carvalho, A. L., & Goloni-Bertollo, E. M. (2014). Methylation as a biomarker for head and neck cancer. Oral Oncology, 50(6), 587-592. doi:10.1016/j.oraloncology.2014.02.015Bagan, J., Sarrion, G., & Jimenez, Y. (2010). Oral cancer: Clinical features. Oral Oncology, 46(6), 414-417. doi:10.1016/j.oraloncology.2010.03.009Bell, R. B., Kademani, D., Homer, L., Dierks, E. J., & Potter, B. E. (2007). Tongue Cancer: Is There a Difference in Survival Compared With Other Subsites in the Oral Cavity? Journal of Oral and Maxillofacial Surgery, 65(2), 229-236. doi:10.1016/j.joms.2005.11.094Bjørge, L., Hakulinen, J., Vintermyr, O. K., Jarva, H., Jensen, T. S., Iversen, O. E., & Meri, S. (2005). Ascitic complement system in ovarian cancer. British Journal of Cancer, 92(5), 895-905. doi:10.1038/sj.bjc.6602334Blom, A. M., Österborg, A., Mollnes, T. E., & Okroj, M. (2015). Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Molecular Immunology, 66(2), 164-170. doi:10.1016/j.molimm.2015.02.029Brailo, V., Vucicevic-Boras, V., Lukac, J., Biocina-Lukenda, D., Alajbeg-Zilic, I., Milenovic, A., & Balija, M. (2012). Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Medicina Oral Patología Oral y Cirugia Bucal, e10-e15. doi:10.4317/medoral.17323Canel, M. (2006). Overexpression of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma Is Independent of fak Gene Copy Number. Clinical Cancer Research, 12(11), 3272-3279. doi:10.1158/1078-0432.ccr-05-1583Canel, M., Secades, P., Garzón-Arango, M., Allonca, E., Suarez, C., Serrels, A., … Chiara, M.-D. (2008). Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. British Journal of Cancer, 98(7), 1274-1284. doi:10.1038/sj.bjc.6604286Cheng, Y.-S., Rees, T., & Wright, J. (2014). A review of research on salivary biomarkers for oral cancer detection. Clinical and Translational Medicine, 3(1), 3. doi:10.1186/2001-1326-3-3Corrales, L., Ajona, D., Rafail, S., Lasarte, J. J., Riezu-Boj, J. I., Lambris, J. D., … Pio, R. (2012). Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. The Journal of Immunology, 189(9), 4674-4683. doi:10.4049/jimmunol.1201654Franzmann, E. J., Reategui, E. P., Pedroso, F., Pernas, F. G., Karakullukcu, B. M., Carraway, K. L., … Goodwin, W. J. (2007). Soluble CD44 Is a Potential Marker for the Early Detection of Head and Neck Cancer. Cancer Epidemiology Biomarkers &amp; Prevention, 16(7), 1348-1355. doi:10.1158/1055-9965.epi-06-0011Hajishengallis, G. (2010). Complement and periodontitis. Biochemical Pharmacology, 80(12), 1992-2001. doi:10.1016/j.bcp.2010.06.017Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., … Stuart, J. M. (2014). Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 158(4), 929-944. doi:10.1016/j.cell.2014.06.049Hu, S., Arellano, M., Boontheung, P., Wang, J., Zhou, H., Jiang, J., … Wong, D. T. (2008). Salivary Proteomics for Oral Cancer Biomarker Discovery. Clinical Cancer Research, 14(19), 6246-6252. doi:10.1158/1078-0432.ccr-07-5037De Jong, E. P., Xie, H., Onsongo, G., Stone, M. D., Chen, X.-B., Kooren, J. A., … Griffin, T. J. (2010). Quantitative Proteomics Reveals Myosin and Actin as Promising Saliva Biomarkers for Distinguishing Pre-Malignant and Malignant Oral Lesions. PLoS ONE, 5(6), e11148. doi:10.1371/journal.pone.0011148Kesselring, R., Thiel, A., Pries, R., Fichtner-Feigl, S., Brunner, S., Seidel, P., … Wollenberg, B. (2014). The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack. European Journal of Cancer, 50(12), 2152-2161. doi:10.1016/j.ejca.2014.05.005Lingen, M. W. (2010). Screening for Oral Premalignancy and Cancer: What Platform and Which Biomarkers? Cancer Prevention Research, 3(9), 1056-1059. doi:10.1158/1940-6207.capr-10-0173Liu, C.-J., Lin, S.-C., Yang, C.-C., Cheng, H.-W., & Chang, K.-W. (2011). Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head & Neck, 34(2), 219-224. doi:10.1002/hed.21713Marimuthu, A., Chavan, S., Sathe, G., Sahasrabuddhe, N. A., Srikanth, S. M., Renuse, S., … Chatterjee, A. (2013). Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834(11), 2308-2316. doi:10.1016/j.bbapap.2013.04.029Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., … Lambris, J. D. (2008). Modulation of the antitumor immune response by complement. Nature Immunology, 9(11), 1225-1235. doi:10.1038/ni.1655McCormack, S. J., Brazinski, S. E., Jr, J. L. M., Werness, B. A., & Goldstein, D. J. (1997). Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene, 15(3), 265-274. doi:10.1038/sj.onc.1201186Menéndez, S. T., Rodrigo, J. P., Álvarez-Teijeiro, S., Villaronga, M. Á., Allonca, E., Vallina, A., … García-Pedrero, J. M. (2012). Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas. Modern Pathology, 25(8), 1069-1078. doi:10.1038/modpathol.2012.63Nitta, H., Wada, Y., Kawano, Y., Murakami, Y., Irie, A., Taniguchi, K., … Imamura, T. (2013). Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88). Clinical Cancer Research, 19(8), 2004-2013. doi:10.1158/1078-0432.ccr-12-1204NITTA, H., MURAKAMI, Y., WADA, Y., ETO, M., BABA, H., & IMAMURA, T. (2014). Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncology Reports, 32(4), 1715-1719. doi:10.3892/or.2014.3341Nunez-Cruz, S., Gimotty, P. A., Guerra, M. W., Connolly, D. C., Wu, Y.-Q., DeAngelis, R. A., … Scholler, N. (2012). Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. Neoplasia, 14(11), 994-IN1. doi:10.1593/neo.121262Pajares, M. J., Agorreta, J., Larrayoz, M., Vesin, A., Ezponda, T., Zudaire, I., … Montuenga, L. M. (2012). Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology, 30(10), 1129-1136. doi:10.1200/jco.2011.37.4231Pardoll, D. (2003). DOES THEIMMUNESYSTEMSEETUMORS ASFOREIGN ORSELF? Annual Review of Immunology, 21(1), 807-839. doi:10.1146/annurev.immunol.21.120601.141135Park, N. J., Zhou, H., Elashoff, D., Henson, B. S., Kastratovic, D. A., Abemayor, E., & Wong, D. T. (2009). Salivary microRNA: Discovery, Characterization, and Clinical Utility for Oral Cancer Detection. Clinical Cancer Research, 15(17), 5473-5477. doi:10.1158/1078-0432.ccr-09-0736Pio, R., Corrales, L., & Lambris, J. D. (2013). The Role of Complement in Tumor Growth. Tumor Microenvironment and Cellular Stress, 229-262. doi:10.1007/978-1-4614-5915-6_11Polanska, H., Raudenska, M., Gumulec, J., Sztalmachova, M., Adam, V., Kizek, R., & Masarik, M. (2014). Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncology, 50(3), 168-177. doi:10.1016/j.oraloncology.2013.12.008Prasad, G., & McCullough, M. (2013). Chemokines and Cytokines as Salivary Biomarkers for the Early Diagnosis of Oral Cancer. International Journal of Dentistry, 2013, 1-7. doi:10.1155/2013/813756Ravindranath, N. M. H., & Shuler, C. (2006). Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas. Journal of Oral Pathology and Medicine, 35(9), 560-567. doi:10.1111/j.1600-0714.2006.00466.xRhodus, N. L., Ho, V., Miller, C. S., Myers, S., & Ondrey, F. (2005). NF-κB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detection and Prevention, 29(1), 42-45. doi:10.1016/j.cdp.2004.10.003Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010). Complement: a key system for immune surveillance and homeostasis. Nature Immunology, 11(9), 785-797. doi:10.1038/ni.1923Rodrigo, J. P., Heideman, D. A. M., García-Pedrero, J. M., Fresno, M. F., Brakenhoff, R. H., Díaz Molina, J. P., … Hermsen, M. A. (2013). Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). International Journal of Cancer, 134(2), 487-492. doi:10.1002/ijc.28355Sainger, R. N. S., Shah, M. H., Desai, A. A., Shukla, S. N., Shah, P. M., Telang, S. D., & Patel, P. S. (2006). Clinical Significance of Serum p53 Antibodies in Oral Cancer. Tumori Journal, 92(2), 134-139. doi:10.1177/030089160609200209Vadrevu, S. K., Chintala, N. K., Sharma, S. K., Sharma, P., Cleveland, C., Riediger, L., … Markiewski, M. M. (2014). Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche. Cancer Research, 74(13), 3454-3465. doi:10.1158/0008-5472.can-14-0157Vaezi, A. E., Bepler, G., Bhagwat, N. R., Malysa, A., Rubatt, J. M., Chen, W., … Niedernhofer, L. J. (2014). Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. Cancer, 120(12), 1898-1907. doi:10.1002/cncr.28643Van der Waal, I. (2010). Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncology, 46(6), 423-425. doi:10.1016/j.oraloncology.2010.02.016Yang, Y., Chung, E. K., Zhou, B., Blanchong, C. A., Yu, C. Y., Füst, G., … Varga, L. (2003). Diversity in Intrinsic Strengths of the Human Complement System: Serum C4 Protein Concentrations Correlate with C4 Gene Size and Polygenic Variations, Hemolytic Activities, and Body Mass Index. The Journal of Immunology, 171(5), 2734-2745. doi:10.4049/jimmunol.171.5.2734Ytting, H., Jensenius, J. C., Christensen, I. J., Thiel, S., & Nielsen, H. J. (2004). Increased activity of the mannan‐binding lectin complement activation pathway in patients with colorectal cancer. Scandinavian Journal of Gastroenterology, 39(7), 674-679. doi:10.1080/00365520410005603Zimmermann, B. G., & Wong, D. T. (2008). Salivary mRNA targets for cancer diagnostics. Oral Oncology, 44(5), 425-429. doi:10.1016/j.oraloncology.2007.09.00